Physician profile
Anantjit Singh
NPI 1245335405
$47,841.50
in general payments reported to CMS, 2019-2025
27 companies · $23K in 2025
The $23K reported for 2025 was more than what 90% of Clinical Cardiac Electrophysiology providers received nationally (typical 2025 total: $2,477).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,218 · 2020: $1,722 · 2021: $2,762 · 2022: $1,056 · 2023: $2,339 · 2024: $11K · 2025: $23K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $24K · Food and Beverage: $6,109 · Travel and Lodging: $4,131 · Consulting Fee: $1,350.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $24,492.67 |
| Food and Beverage | $6,109.41 |
| Travel and Lodging | $4,130.77 |
| Consulting Fee | $1,350.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $22,051.21 | 2019-2025 | Lifevest |
| Kestra Medical Technology Services, INC. | $13,521.83 | 2022-2025 | Assure Wcd |
| Medtronic, INC. | $6,102.97 | 2021-2025 | Micra, Pulseselect, Cobalt Dr Mri Surescan |
| Medtronic Vascular, INC. | $1,932.42 | 2019-2020 | |
| Atricure, INC. | $1,806.77 | 2019-2025 | Atriclip Laa Exclusion System |
| Boston Scientific Corporation | $978.53 | 2019-2024 | Bodyguardian |
| Biosense Webster, INC. | $317.82 | 2021-2025 | Carto 3, Nuvision Ice Catheter, Qdot Micro |
| Novartis Pharmaceuticals Corporation | $261.93 | 2019-2023 | |
| Biotronik INC. | $110.05 | 2023-2024 | Biomonitor, Renamic Neo |
| Sanofi-Aventis U.S. LLC | $86.68 | 2019-2021 | |
| Medical Device Business Services, INC. | $82.49 | 2019 | |
| Becton, Dickinson and Company | $81.71 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $67.45 | 2019-2024 | Eliquis |
| Convatec INC. | $65.33 | 2024-2025 | |
| Pfizer INC. | $62.84 | 2019-2020 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Impulse Dynamics (USA) INC. | $46.79 | 2024 | Optimizer |
| Janssen Pharmaceuticals, INC | $45.95 | 2019-2021 | |
| Teleflex LLC | $34.30 | 2019-2023 | Guideliner |
| Amgen INC. | $32.61 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $23.82 | 2020 | |
| Merck Sharp & Dohme LLC | $22.56 | 2024 | Verquvo |
| Bayer Healthcare Pharmaceuticals INC. | $21.45 | 2021 | |
| Amarin Pharma, INC. | $19.86 | 2020 | |
| Cardiva Medical, INC. | $19.72 | 2025 | Cardiva Vascade Mvp Vvcs 6-12f |
| Gilead Sciences, INC. | $16.26 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.12 | 2025 | Jardiance |
| Cvrx, INC. | $13.03 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anantjit Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.